VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
UPC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
UPCUniverse Pharmaceuticals Inc.
$4.69$3M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
UPC logo

Universe Pharmaceuticals Inc.

UPC
NASDAQ · Specialty & Generic Pharma
$4.69
At close - Sep 23, 4:00 PM EDT - USD
Market Cap$3M
P/E-0.0x
52W High$17.96
Volume18.68K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2025Q4

Persistent Revenue Erosion Challenges Long-Term Viability

Universe Pharmaceuticals faces a structural decline in its core distribution business, evidenced by a 14.1% year-over-year revenue contraction in 2025Q4. While the company maintains a healthy liquidity position with $33.6M in cash, the lack of operating levera...

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

UPC price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

No Data

No recent earnings data

02

Valuation risk

-100% Peers

P/E is 100% below peer median

03

Market leadership

RS 90 · Leader

High momentum (Outperforming 90% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystNext earnings unconfirmed

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
UPC+12.75%
S&P 500 (^GSPC)+12.39%
1-Year Return
UPC+13.02%
S&P 500 (^GSPC)+15.77%
3-Year Return
UPC-99.30%
S&P 500 (^GSPC)+78.04%
5-Year Return
UPC-99.94%
S&P 500 (^GSPC)+73.44%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-0.0x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-0.0x
4.1x
0th· Low
EV/EBITDA
N/A
3.1x
N/A
Price/FCF
N/A
3.1x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue
$18M-22.4% YoY
Net income
-$4M+57.9% YoY
Free cash flow
-$5M+45.3% YoY
Operating margin
-16.3%+18.5 pts YoY
ROIC (TTM)-7.8%
Avg ROIC 5Y-
ROE (TTM)-7.2%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

MARKET COVERAGE

Latest News

2 Stories
GlobeNewsWire·Jun 26, 2026
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Globe News Wire·Jun 26, 2026
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited ("Best Praise"), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Filtered for Universe Pharmaceuticals Inc.More Headlines
04

Compare before deciding

Benchmark UPC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Universe Pharmaceuticals Inc. (UPC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
UPC logoUPCUniverse Pharmaceuticals Inc.Current
$4.69$2.64M-0.00-22.44%-20.56%-7.23%—
HCWB logoHCWBHCW Biologics Inc.
$1.66$577.08K-0.03-97.89%-73.22%-142.16%—
XTLB logoXTLBXTL Biopharmaceuticals Ltd.
$2.20$242.07K-0.23—-227.72%-25.53%—
NUVB logoNUVBNuvation Bio Inc.
$5.71$1.98B-9.52698.96%-88.19%-49.73%—
CPRX logoCPRXCatalyst Pharmaceuticals, Inc.
$31.49$3.85B18.7419.78%37.08%23.65%—
TLPH logoTLPHTalphera, Inc.
$1.16$60.2M-3.41—-1507600%-87.28%—

Compare UPC vs Peers

Universe Pharmaceuticals Inc. (UPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HCWB

Most directly comparable listed peer for UPC.

Scale Benchmark

vs MCK

Larger-name benchmark to compare UPC against a more recognizable public peer.

Peer Set

Compare Top 5

vs HCWB, XTLB, NUVB, CPRX

Get notified when UPC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

UPC Frequently Asked Questions

Universe Pharmaceuticals Inc. (UPC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Universe Pharmaceuticals Inc.'s revenue?

Universe Pharmaceuticals Inc. (UPC) reported $40.9M in revenue for fiscal year 2025. This represents a 43% increase from $28.5M in 2018.

How fast is Universe Pharmaceuticals Inc. growing?

Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 22.4% over the past year.

Is UPC profitable?

Universe Pharmaceuticals Inc. (UPC) reported a net loss of $12.4M for fiscal year 2025.

Dividend & Returns
What is UPC's return on equity?

Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -7.2%. Negative ROE indicates the company is unprofitable.

What is Universe Pharmaceuticals Inc.'s free cash flow?

Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in UPC back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →